A small biotech company is getting a big boost from artificial intelligence in its search for cancer treatments. Instead of relying only on lab tests and guesswork, the firm is using AI to speed up how it designs and picks new drug candidates. This approach isn’t just a small tweak—it’s reshaping ho
A new experimental drug from Novartis is making waves in the fight against prostate cancer. Early trial results show it shrinks tumors in patients, even those who stopped responding to the company's existing treatment, Pluvicto. The drug uses a different radioactive element called actinium-225, whic
ALS is a rare but cruel disease that slowly shuts down the body while leaving the mind intact. Doctors have only approved three drugs for it since the mid-1990s, and none of them cure or stop the disease—they merely slow it down a little. Part of the problem is money. Running trials for ALS is extre
In Canada, researchers often submit applications to ethics boards before starting a study. These forms normally ask for basic details about the trial, but they rarely prompt investigators to think about who will benefit from the research or how patients will be involved in decisions. The study lo
Doctors in the U. S. now have another tool to fight a tough cancer. The FDA gave the green light for early use of an experimental pill called daraxonrasib. It targets pancreatic ductal adenocarcinoma, a fast-spreading form of pancreatic cancer that has already resisted other treatments. Patients who
Research on semaglutide, a once-a-week shot, shows it can help people lose noticeable weight—up to one-sixth of their body weight in some cases. Trials called STEP 1, 3, and 4 focused on adults without diabetes and found weight drops between ten and seventeen percent. For those with type 2 diabetes
For decades, drug testing followed the same slow rhythm. Researchers ran trials in stages, then paused for months to analyze data before asking regulators for the next step. Patients waited years for treatments while paperwork piled up. Now, a new FDA approach cuts out the waiting by letting regulat
Quick action saves lives when someone has a heart attack. That’s why some emergency teams now give aspirin on the spot. But does this practice hold up under real-world conditions? A study called CELEBRATE looked at whether early aspirin use actually helps patients before they even get to the hospita
A French biotech company just got a two-year break from paying back millions in loans, giving it more cash to push forward on cutting-edge research. The firm, known for developing treatments targeting tough diseases, reached a deal with lenders to delay loan payments totaling around €17. 8 million.
Back in 2009, a small group of experts started giving free, no-nonsense feedback to anyone trying to turn a muscle-disease idea into a real treatment. Their main job was to stop bad drugs from reaching patients too early, and to make sure good drugs had a fair shot at proving they worked. Over 15 ye
